Rock Point Advisors, LLC Gilead Sciences, Inc. Transaction History

Rock Point Advisors, LLC

$358 Million
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $1.36 Million - $1.95 Million	-21,764 Reduced 46.2%	25,340 $2.18 Million
Q3 2022 Nov 10, 2022	SELL	$59.54 - $68.01 $29,174 - $33,324	-490 Reduced 1.03%	47,104 $2.91 Million
Q2 2022 Aug 10, 2022	SELL	$57.72 - $65.01 $2.02 Million - $2.27 Million	-34,961 Reduced 42.35%	47,594 $2.94 Million
Q1 2022 May 10, 2022	BUY	$57.92 - $72.58 $11,584 - $14,516	200 Added 0.24%	82,555 $4.91 Million
Q4 2021 Feb 09, 2022	BUY	$64.88 - $73.64 $1.81 Million - $2.05 Million	27,826 Added 51.03%	82,355 $5.98 Million
Q3 2021 Nov 05, 2021	SELL	$67.69 - $73.03 $15,907 - $17,162	-235 Reduced 0.43%	54,529 $3.81 Million
Q2 2021 Aug 05, 2021	BUY	$63.47 - $69.35 $65,691 - $71,777	1,035 Added 1.93%	54,764 $3.77 Million
Q1 2021 May 12, 2021	BUY	$60.0 - $68.46 $69,240 - $79,002	1,154 Added 2.19%	53,729 $3.47 Million
Q4 2020 Feb 08, 2021	BUY	$56.65 - $64.55 $1.22 Million - $1.39 Million	21,537 Added 69.39%	52,575 $3.06 Million
Q3 2020 Nov 10, 2020	BUY	$62.1 - $78.08 $146,990 - $184,815	2,367 Added 8.26%	31,038 $1.96 Million
Q2 2020 Aug 12, 2020	SELL	$72.34 - $84.0 $2.08 Million - $2.41 Million	-28,741 Reduced 50.06%	28,671 $2.21 Million
Q1 2020 May 07, 2020	SELL	$62.63 - $80.22 $5.16 Million - $6.61 Million	-82,340 Reduced 58.92%	57,412 $4.29 Million
Q4 2019 Feb 06, 2020	BUY	$61.62 - $67.78 $154,974 - $170,466	2,515 Added 1.83%	139,752 $9.08 Million
Q3 2019 Nov 08, 2019	BUY	$62.51 - $69.0 $272,481 - $300,771	4,359 Added 3.28%	137,237 $8.7 Million
Q2 2019 Aug 12, 2019	BUY	$61.87 - $69.38 $49,434 - $55,434	799 Added 0.6%	132,878 $8.98 Million
Q1 2019 May 08, 2019	BUY	$62.53 - $70.05 $500 - $560	8 Added 0.01%	132,079 $8.59 Million
Q4 2018 Jan 31, 2019	SELL	$60.54 - $79.0 $436,311 - $569,353	-7,207 Reduced 5.17%	132,071 $8.26 Million
Q3 2018 Nov 07, 2018	SELL	$71.28 - $78.92 $29,581 - $32,751	-415 Reduced 0.3%	139,278 $10.8 Million
Q2 2018 Aug 09, 2018	BUY	$64.88 - $75.68 $1.67 Million - $1.95 Million	25,783 Added 22.63%	139,693 $9.9 Million
Q1 2018 May 11, 2018	SELL	$72.84 - $88.8 $231,631 - $282,384	-3,180 Reduced 2.72%	113,910 $8.59 Million
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $56,493 - $66,314	794 Added 0.68%	117,090 $8.39 Million
Q3 2017 Nov 03, 2017	BUY	$72.11 - $85.47 $8.39 Million - $9.94 Million	116,296	116,296 $9.42 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Point Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rock Point Advisors, LLC with notifications on news.

Account